Videos

A pair of psychiatrists discuss how climate change and other social determinants of health are affecting the mental wellbeing of indigenous people.

It takes even more than a village to provide the comprehensive care needed for aging, neurocognitive patients, says Rajesh R. Tampi, MD, MS.

Rajesh R. Tampi, MD, MS, discusses the evolved definition of dementia as a cognitive disorder, and how its spectrum of symptoms impact clinical development.

Christian Lillis of the Peggy Lillis Foundation for C. Diff Education & Advocacy discusses the need for greater industry-organization support and drug development.

Results from the 2 APPaRENT trials suggest regular inhaled corticosteroids/LABA alone or with short-acting beta agonists were the preferred treatment approach with physicians.

Dr. Richmond speaks to the newest pulmonology data from Vanderbilt University that was presented at ATS 2022.

Dr. Rizzo sits down with HCPLive to discuss the impact of air pollution and allergies on pulmonary health, as well as new research on pulmonary arterial hypertension.

Dr. Tara Vijayan talks about how primary care physicians can be best combat misinformation.

Alcohol use increased during the COVID-19 pandemic, leading to an increase in alcoholic hepatitis.

There remains a need to develop more antivirals that can be easily scaled up for COVID-19.

Theresa R. Cerulli, MD, discusses the known clinical profile and evidential potential of the newest non-stimulant ADHD drug for adults.

There is concern for cardiovascular patients over missed screenings during the pandemic.

On the heels of the FDA approval of viloxazine extended-release capsules for adult ADHD, a neuropsychiatrist discusses the state of care and diagnosis among older patients.

In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.

From curative stem cell approaches to in-clinic subretinal injections, Arshad Khanani, MD, MA, navigates what the future drug class may entail.

An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.

Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.

Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.

Dr. Levine is joined by Dr. Sanjay Mathew to talk about some exciting treatments in the pipeline for psychiatric disorders.

Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.

Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.

An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.

Matthew Cunningham, MD, explains the need for greater inclusion of impacted races and ethnicities in ophthalmic clinical trials.

Stephanie Lovinsky-Desir, MD, MS, discusses key findings from the 2022 ALA State of the Air Report.

Erica Marsh, MD, MSCI, discusses the role of new drug classes like GnRH antagonists, as well as the adoption of remote screening options following COVID-19 response.

Erica Marsh, MD, MSCI, discusses the need for improved patient involvement and open discussion in the highly prevalent, potentially psychologically impactful condition.

There are several emerging treatments for C difficile infections.